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Abstract
Background: The E2 glycoprotein is an important encoded hepatitis C virus (HCV) protein that contains three different variable regions.
Objectives: The aim of the present study was to construct an HCV 1a/JFH1 chimeric virus by replacing the intergenotypic variable region (igVR)
fragment of the highly variable region of the E2 gene of the Japanese Fulminant hepatitis genotype 2a JFH1 virus with a similar region of HCV genotype
1a. This chimera was produced as a model virus with the ability to be cultured. We analyzed the adapted virus and the variations of nucleic acids
within it.
Methods: Specific primers were designed for the igVR of HCV genotype 1a followed by the overlap-PCR method for the synthesis of the desired DNA
fragment. The amplified igVR-1a chimera gene and pFL-J6/JFH were digested by KpnI and BsiWI restriction enzymes, and the fragment was ligated
into pFL-J6/JFH. The recombinant vector was transformed into Escherichia coli JM109 strain competent cells. All clones were confirmed by colony PCR
using specific primers, and the confirmed recombinant vector was sequenced. The recombinant vector was targeted for RNA synthesis by T7 RNA
polymerase enzyme. RNA transfection was performed in the Huh7.5 cell line. Virus production in several passages and the evaluated viral load were
studied using quantitative real-time PCR and ELISA methods. After 30 passages, the RNA virus was extracted and cloned in PCDNA3.1 vector, and was
then sequenced
Results: Quantitative real-time PCR results showed 11,292,514 copies/mL of chimeric virus production in cell culture. The virus production was con-
firmed using ELISA, which showed a virus core production of 808.2 pg/mL. The results of cloning and sequencing showed that some of the nucleic
acids in the chimera virus were changed, affecting the viral behavior in the cell culture.
Conclusions: Real-time PCR and ELISA showed high levels of production of 1a/JFH1 chimeric HCV in the Huh7.5 cell culture. The constructed virus
can be used for future studies, including the development of new HCV drugs and vaccines.
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1. Background
Hepatitis C virus (HCV) is an enveloped, single-
stranded RNA virus belonging to the Flaviviridae family (1,
2). It is estimated that more than 3% of the world’s popu-
lation is infected with HCV (1). In many patients, chronic
infection with HCV may cause liver disorders, such as cir-
rhosis, or more severe diseases, such as hepatocellular car-
cinoma (3). HCV is classified into seven major genotypes
with more than 80 subtypes (4). According to various
climatic conditions and transmission routes, different
statistics are reported for the HCV genotype distribution
in each country or region. In Iran, HCV genotypes 1a and
3a have been reported to be more frequent, with 41.7% and
33.0% prevalence rates, respectively (2). The HCV genome
is a circular RNA that encodes a large, 3,000-amino-acid
polyprotein that is cleaved into different structural and
non-structural proteins (5). The four structural proteins
are the core protein (22 kDa), the glycoproteins E1 (33 kDa)
and E2 (70 kDa), and p7. The non-structural (NS) proteins
are NS2, NS3, NS4A, NS4B, NS5A, and NS5B (6). Among the
structural proteins encoded by HCV, the E2 glycoprotein
plays an important role in the binding and entry of the
virus into hepatic cells. As such, it has been shown that the
production of neutralizing antibodies (NAb) against the
E2 protein receptor binding sites prevents HCV infection
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in chimpanzees (7); this has effectively eliminated the
virus in humans as well (8). Therefore, the induction of
NAb against HCV E2 would be an effective strategy for the
production of vaccines against the virus. The HCV E2 gly-
coprotein itself consists of three variable surface regions,
including a highly variable region, the central region of
the E2 protein, which is separated by disulfide bonds, and
the intergenotypic variable region (igVR) which is located
at the third region of the E2 protein, which is separated
by disulfide bonds, and the intergenotypic variable region
(igVR) are located at the third region of the E2 glycopro-
tein (amino acids 431 - 466) (9). The igVR is known to
be involved in viral attachment to specific liver surface
receptors (such as CD81 and SR-BI) and virus entry into the
hepatic cells (10). Although the igVR is relatively the same
among similar genotypes of HCV, it shows a high degree
of variability between different genotypes (10). Currently,
among the HCV genotypes, HCV genotype 2a (known as
JFH1) has the ability to be cultured in vitro. Accordingly,
there have been many efforts to create HCV chimeras and
identify the mutations; however, the production of an
attenuated vaccine against HCV is the main goal. One of
the innovative aspects of this project was the construction
of a combined virus of the two genotypes, using genetic
engineering. The chimeric virus will be used in future
studies for reverse genetic analysis to investigate the
behavior of HCV in cell cultures.
The innovation of this project was to produce a
chimera virus with a combination of genotypes 1a and 2a.
The 1a genotype has a high prevalence in Iran and the 2a
(JFH1) genotype has the ability to be cultured in vitro. Our
study’s plan is in line with other large-scale projects to de-
velop a vaccine for hepatitis C. This study was designed
to take steps toward the production of a vaccine against
this native virus in Iran (genotype 1). Evaluation of the
immunogenicity of E2 glycoprotein peptides was another
goal in this study. This region is important because it is the
virus attachment site on the cell surface and affects gene
sequence changes among genotypes.
2. Objectives
In the present study, we replaced the genotype 1 E2 vari-
able glycoprotein regions with the same part in genotype
2.
3. Methods
3.1. Primer Design and PCR Amplification
In this study, we used plasmids pFL-J6/JFH (genotype
2a) and pSGR-JFH1 (GND). The pSGR-JFH1 (GND) plasmid
has a point mutation in NS5B (G8624A), which can be
used as a negative control. We also retrieved the geno-
type 1 sequence from the NCBI database and designed the
primers based on this data. These plasmids were trans-
ferred into Escherichia coli strain JM109 and purified using a
QIA prep Miniprep kit (Qiagen, USA) according to the man-
ufacturer’s recommendations. The concentrations of the
pFL-J6/JF and pSGR-JFH1 plasmids DNA were detected using
the optical density (OD) method, as well as agarose gel elec-
trophoresis.
3.2. Construction of the igVR-1a/JFH1 Chimera Genome
Two pairs of specific primers were designed for ampli-
fying the chimeric region. These primers contained the
BsiWI (Bold letters in the forward 1 primer) and KpnI (Bold
letters in the reverse 2 primer) restriction enzyme cleav-
age sites (Table 1). Gene amplification was carried out us-
ing a thermal cycler system (Applied Biosystems, USA). All
PCR products were checked using 1.5% agarose gel and
were stained with Green viewer stain (CinnaGen, Iran), and
the results were visualized under an ultraviolet (UV) light
source using a GelDoc system (Genius3 Syngene, UK).
PCR was performed to produce the first set of frag-
ments. The PCR reaction mixture contained 5 µg of DNA
sample (JHF1) (11), 1.5 mM of MgCl2 (CinnaGen, Iran), 0.8
mM of each dNTP (CinnaGen, Iran), 10 pmol of each primer
(forward 0.8 and reverse 0.8 primers), and one unit of Taq
DNA polymerase 5 u/µL (CinnaGen, Iran). Gene amplifica-
tion was carried out using the following protocol: after an
initial denaturation step of 95°C for 3 minutes, there were
28 cycles (95°C for 30 seconds, 59°C for 45 seconds, 72°C
for 30 seconds), and a final annealing step of 72°C for 7
minutes. The second fragment’s PCR reaction mixture con-
tained 1 µg of DNA sample (JHF1), 3 mM of MgCl2 (Cinna-
Gen, Iran), 0.3 mM of each dNTP (CinnaGen, Iran), 10 pmol
of each primer (forward 2 and reverse 2 primers, Table 1),
and one unit of Taq DNA polymerase 5 u/µL (CinnaGen,
Iran). After an initial denaturation step of 95°C for 4 min-
utes, there were an additional 30 cycles (93°C for 1 minute,
58°C for 30 seconds, 72°C for 50 sec), and a final anneal-
ing step of 72°C for 3 minutes. In the final PCR round, the
overlap-PCR reaction was performed using 7 µL of the first
and second PCR products (approximately 5µg of template
DNA of each product), 2.5 mM of MgCl2, 0.4 mM of each
dNTP, and two units of Taq DNA polymerase 5 u/µL (Cinna-
Gen, Iran).
The first round of gene amplification was carried out
for 5 cycles (95°C for 1 minute, 65°C for 50 seconds, 72°C
for 45 seconds), followed by the addition of 0.8 µL of 10
pmol primers (forward 1 and reverse 2 primers, Table 1). The
second round of amplification was performed for 28 cycles
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Table 1. Properties of the Forward and Reverse Primers Used for Amplifying the Chimeric Region







aThese primers consisted of the BsiWI (bolded in the forward 1 primer) and KpnI (bolded in the reverse 2 primer) restriction enzyme cleavage sites.
bTwo primers consisted of the overlapping part, bolded in the reverse 2 and forward primers.
(95°C for 40 seconds, 60°C for 50 seconds, 72°C for 45 sec-
onds), and a final extension of 72°C for 3 minutes. The fi-
nal PCR products (1645 bp) were purified using a commer-
cial kit (Bioneer, South Korea) according to the manufac-
turer’s recommendations. The amplified igVR-1a chimera
gene and JFH1 vector were digested using the KpnI and
BsiWI restriction enzymes (New England Biolabs, UK) and
the digested products were purified using a commercial
kit (Bioneer, Korea) according to the manufacturer’s rec-
ommendations. The ligation mixture was prepared as fol-
lows: 0.8 µL of T4 DNA ligase (Fermentas, USA), 1 µL of
10× T4 DNA ligase buffer, 180 ng of purified linear JFH1 vec-
tor, 50 ng of purified igVR-1a chimera fragment, and 0.5
µl of 50% PEG 4000 solution. This mixture was prepared
and incubated at 14°C overnight. The ligation product was
transformed into E. coli JM109 strain competent cells, as de-
scribed previously (12). The presence of the igVR-1a chimera
clone was confirmed by colony PCR using the forward 1 and
reverse 2 specific primers (Table 1) and a restriction enzyme
analysis. The confirmed cloned fragments were used for
purification with a commercial kit (Qiagen, USA) accord-
ing to the manufacturer’s recommendations.
3.3. Sequencing
The cloned fragments were purified and sent for se-
quencing to Bioneer (Korea). The sequencing results were
blasted.
3.4. In vitro RNA Transcription
The igVR-1a chimera gene, GND, and JFH1 vectors were
digested with the XbaI restriction enzyme (Roche, USA).
For in vitro RNA transcription, mung bean nuclease cata-
lyst was used in the degradation of single-stranded DNA
and RNA (Promega, USA). In vitro RNA transcription was
performed with a MEGAscript T7 kit (Ambion, Germany)
according to the manufacturer’s recommendations. After
DNase I treatment, RNA was used for transfection (12).
3.5. Cell Culture
The necessary amount of the Huh7.5 cell line was re-
ceived from the Pasteur institute of Iran. This cell line was
grown in Dulbecco’s modified minimal essential medium
(DMEM) (Gibco, USA) supplemented with 100 U/mL of
penicillin, 100 µg/mL of streptomycin antibiotics (Gibco,
Germany), 10% (v/v) heat-inactivated fetal bovine serum
(Gibco, Germany), and 1 M of HEPES buffer solution (Invit-
rogen, USA). The Huh7.5 cells were incubated at 37°C in a 5%
CO2 environment (12).
3.6. RNA Transfection and Infection of Huh7.5 Cells
The Huh7.5 cells were seeded at a density of 3 × 104
cells/well in 24-well plates, then cultured at 37°C overnight
in DMEM medium. The confluency of cells reached 70%.
RNA transfection was performed using DMRIE-C (Invitro-
gen, USA) in accordance with the manufacturer’s specifi-
cations. After transfection, the supernatants of the cul-
tured cells were harvested and stored at -70°C. The Huh7.5
cells were seeded at a density of 3×104 cells/well in 24-well
plates. Next, the cells were grown at 37°C for 24 hours
in complete DMEM medium. As a result, the confluency
of cells reached 60% - 70%. The supernatant of the previ-
ous step was transferred to the Huh7.5 cells. Finally, after
24 hours, the supernatants of the cultured cells were har-
vested and stored at -70°C.
3.7. Real-Time PCR of igVR-1a Chimera Virus
Total viral RNA was extracted from 140 µL of the stored
supernatant of the cultured cells using a QIAamp viral RNA
kit (Qiagen, USA) according to the manufacturer’s recom-
mendations. Real-time PCR was performed using a com-
mercial kit (Genome Diagnostics Pvt., New Delhi, India)
(12).
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3.8. Enzyme-Linked Immunosorbent Assay (ELISA)
HCV core antigen detection ELISA assay kits (XC-1000,
USA) were used for igVR-1a chimeric virus detection. ELISA
was performed for the core protein to evaluate the pro-
duction of active virus. After transfection of RNA virus in
Huh7.5 cells, all virus proteins were assembled and the ac-
tive virus was produced.
3.9. IgVR-1a Chimera Virus Infection of Huh7.5 Cells
Supernatants of the igVR-1a chimera virus were used to
infect Huh7.5 cell cultures. Cell-free supernatants were in-
fected for 30 passages and then harvested and stored at -
70°C.
3.10. Cloning and Sequencing
After 10 passages of viral RNA, the igVR-1a chimera virus
was extracted. RNA concentration was measured using a
bioanalyzer device (NanoDrop 2000, Germany). In order
to eliminate the plasmid vector, DNase I (Fermentas, USA),
was used. In addition, cDNA production was analyzed with
a PCR kit (Fermentas, USA). PCR and standard cloning pro-
cedures for the PCDNA3.1 vector were performed with ap-
propriate restriction sites in forward and reverse primers,
where the HindIII and EcoRI (Roche, Germany) restriction
enzymes were applied. The primer sequences were as fol-
lows: forward 1: 5’-AACTAAGCTTTGATGATGAACTGGTCG-3’,
reverse 1: 5’-AACTGAATTC AAGCAACGCCAAAAGCC-3’ (frag-
ment length 1720 bp). Next, PCR was performed using a
thermal cycler (Applied Biosystems, USA). The final PCR
product purification (1735 bp) and the final plasmid igVR-1a
chimera colonies were performed using a commercial kit
(Bioneer, South Korea). All plasmids of the igVR-1a chimera
were then confirmed by colony PCR with forward and re-
verse specific primers, as well as sequencing (Macrogen,
Korea).
4. Results
The igVR-1a chimera gene was amplified using the
overlap-PCR method. The amplified fragments (1-2) and the
final fragment had an expected size of 750 bp, 895 bp, and
1645 bp, respectively (Figure 1). After digestion with restric-
tion enzymes, the DNA fragments containing the igVR-1a
chimera gene were cloned into the JHF1 vector.
Double digestion of the igVR-1a chimera gene was done
with the KpnI and BsiWI restriction enzymes (Figure 2). The
igVR-1a chimera gene was digested with the XbaI restric-
tion enzyme and in vitro RNA transcription (Figure 3). The
standard curve of the ELISA assay kit for HCV core was used
for igVR-1a chimeric virus detection (Figure 4). The igVR-
1a chimera gene was cloned and purified. The results of
Figure 1. Gel electrophoresis of the first PCR amplification using forward 1/reverse 1
(lane 1), forward 2/reverse 2 (lane 2), and forward 1/reverse 2 (lane 4; final fragment)
primers; lane 3, 1 kb DNA size-marker (Fermentas, USA).
sequencing showed that all fragments were 100% identi-
cal and had no gaps. After reaching almost identical RNA
concentrations of igVR-1a and JFH1 in the same number
of cultured cells, transfection was done. Next, virus pro-
tein production was performed using the ELISA method for
evaluating the core protein of the virus. In order to exam-
ine the viability of the infectious virus, ELISA and real-time
PCR were used after passages 1, 5, and 10. The ELISA report
showed that JFH1 proliferated in passages 1, 5, and 10 (280.6,
367.6, and 621 pg/mL, respectively). Chimeric virus concen-
trations after passages 1, 5, and 10 were 34.5, 253.5, and 808.2
pg/mL, respectively. Real-time PCR results showed that JFH1
produced virus in passages 1, 5, 10, and 30 (5,017, 378,491,
12,615,815, and 13,390,851 copies/mL, respectively), while the
chimeric virus titers after passages 1, 5, 10, and 30 were
6,040, 92,510, 5,933,449, and 11,292,514 copies/mL, respec-
tively. Statistical analyses, such as correlation tests, were
used to compare between the real-time PCR and ELISA re-
sults. There was no significant correlation between real-
time PCR and ELISA results for igVR-1a (P > 0.05) (Figure 6).
Correlation between real-time PCR and ELISA results was
calculated with Pearson’s correlation test. Comparison of
virus production during passages 1, 5, 10, and 30 with real-
time PCR results in igVR-1a and JFH1 are shown in Figures
7 and 8. The GND plasmid as a negative control was not
able to produce the virus. The construction of the igVR-1a
chimera virus did not have any mutations, but an analysis
4 Hepat Mon. 2016; 16(10):e38261.
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Figure 2. Gel Electrophoresis of Double-Digestion of the igVR-1a Chimera Gene
Lane 1, double-digested igVR-1a chimera plasmid; lane 2, undigested igVR-1a chimera
plasmid; lane 3, 1 kb DNA size-marker (Fermentas, USA).
of 30 passages of nucleic acids and amino acid sequences
showed a change in their sequence.
5. Discussion
In the present study, we successfully developed a novel
HCV chimera by substituting the igVR in the JFH1 subtype
with that of genotype 1a. HCV is an enveloped, single-
stranded RNA virus belonging to the Flaviviridae family (1).
It is estimated that more than 3% of the world’s popula-
tion is infected with HCV. Chronic HCV infections may pre-
dispose many patients to more serious liver disorders, in-
cluding cirrhosis and hepatocellular carcinoma (3). The
HCV genome is a circular RNA that encodes a large, 3,000-
amino-acid polyprotein, which is cleaved onto different
structural and non-structural proteins. Structural pro-
teins include the core, the E1 and E2 glycoproteins, and
a small p7 protein. The E1 (amino acids 193 - 383 of the
polyprotein) and E2 (amino acids 384 - 746) glycoproteins
of HCV are type I transmembrane proteins (13). The infec-
tious viral particles of HCV (HCVpp) contain non-covalent
E1E2 heterodimers. These viral particles are able to infect
the primary human liver cells and various human hep-
Figure 3. Gel Electrophoresis Results of RNA Synthesis
Lanes 1 and 2, RNA synthesis of igVR-1a chimera gene and RNA size marker, respec-
tively.



















The standard curve was prepared by the serial dilution method (2000 - 1000 - 500 -
250 - 125 pg/mL).
atic cell lines, such as Huh7 (14). They are considered an
alternative model for studying the virus-entry phase and
entry inhibition. Glycoprotein E1 is pivotal for viral en-
try into the target cell; an HCVpp without it is not infec-
tious (14). E2 contains 11 glycosylation sites and 18 con-
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Figure 5. Five standards were used, in 2.5×103 IU/mL to 2.5×107 IU/mL concentrations, measured by Rotor Gene. Real-time PCR results showed JFH1 chimeric virus titer in the
cell culture.
r: 0.915 






















Figure 6. Correlation Between Real-Time PCR and ELISA Results in igVR-1a
served cysteine residues. Alignment of diverse E2 glyco-
protein sequences across the six major genotypes revealed
three variable regions between residues 570 and 580. HVR1,
HVR2, and igVR are flexible structures in the surface re-
gion of the E2 protein that regulate the function of the
E1E2 heterodimer and prevent the neutralizing antibod-
ies from having access to the conserved and central con-
stant region. Due to the presence of disulfide bonds, this
region is protected against proteolytic activity. The vari-
able regions of the E2 glycoprotein play an important role
in the induction of the humoral immune response (14).
The production of HCV chimeras has been an interesting
branch of research since culturing of the JFH1 strain in the
Huh7.5 cell line was first successful. Gottwein et al. suc-
ceeded in creating an intergenotypic 3a/2a chimera con-
taining the core, E1, E2, p7, and NS2 of the 3a genotype,
which was able to be cultured in Huh7.5 cells (15). Lu et
al. also constructed a cultivable infectious intergenotypic
1b/JFH1 chimera containing the core, E1, E2, p7, and the first
transmembrane domain of NS2 from genotype 1b (16). Yi et
al. constructed chimeric genomes encoding the structural
proteins of genotype 1a within the backbone of JFH1 (17).
In the present study, we successfully created a novel HCV
chimera by substituting the igVR in the JFH1 subtype with
that of genotype 1a. Our results suggest that the generated
chimera is cultivable, can produce RNA in cell cultures, and
is able to assemble and produce infectious particles. These
robust intergenotypic recombinant cell culture systems
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Figure8. Comparison of Virus Production During Passages 1, 5, 10, and 30 with ELISA
for HCV will provide opportunities to further study differ-
ent HCV genotypes and evaluate related pharmacothera-
peutics. Moreover, alongside creating cultivable chimeras,
compensatory mutations essential for the in vitro produc-
tion of an infectious virus was identified in the aforemen-
tioned studies. Pietschmann et al. created a series of in-
tergenotypic and intragenotypic chimeric genomes allow-
ing the production of infectious HCV genotype 1a, 1b, 2a,
and 3a particles. Moreover, it was shown that a polyclonal
IgG derived from a mouse immunized with a recombinant
vaccine consisting of the E1 protein from genotype 1a was
able to neutralize the infectivity of HCV genotype 2a, 1a, 1b,
and 3a particles (18).
According to a previous study by Meshkat et al. (11), Iran
has a high prevalence of HCV genotype 1. Unfortunately,
this genotype cannot be cultured in vitro to analyze the be-
havior of the virus. On the other hand, the igVR of the
virus’s surface glycoprotein E2 is highly effective at binding
to the hepatocyte receptor. In this project, we exchanged
this part of the virus with the same region of the JFH1 (geno-
type 2) glycoprotein E2 and created an active chimera virus
in cell culture. We studied the structure and behavior of
the virus and multiple mutations of glycoprotein E2, in
order to investigate the survival, adaptation, and replica-
tion of the chimera virus in cell culture. After 30 passages,
we observed changes in the amino acids of igVR-1a in the
chimera virus, where Cys was exchanged with Val. Val was
also exchanged with Thr, and Gly was replaced by Ala. The
observed changes might result in alterations in the three-
dimensional structure of the proteins, such as the changes
in the enveloped E2 glycoprotein on the surface of HCV.
These variations affected the binding of HCV with cell re-
ceptors and therefore resulted in changes in the pathogen-
esis of HCV.
The aim of this project was to produce a chimera virus
as a combination of genotypes 1a and 2a. The 1a genotype
has a high prevalence in Iran and the 2a (JFH1) genotype
has the ability to be cultured in vitro. Our objective was to
evaluate the structure of the nucleic acids and amino acids
of the chimera virus. We replaced the igVR between the
two genotypes to produce HCVpp. Next, we analyzed this
chimera virus with ELISA and real-time PCR. Chimeric HCV-
1a produced additive concentrations in cell-culture sys-
tems and the novel HCV chimera in all passages in the cell
cultures, such as JFH1. These novel intergenotypic recom-
binant viruses, using the backbone of the JFH1 virus and
the igVR of genotype 1a, were tested in an animal model
and the immune responses were analyzed. The results can
be used for reverse genetic studies and research into neu-
tralizing antibodies, virus assembly, and vaccine develop-
ment.
5.1. Conclusion
In the present study, we successfully created a novel
HCV chimera using the backbone of the JFH1 virus and the
igVR of genotype 1a. Our chimeric virus proliferated in
Huh7.5 cell cultures and produced infectious viral parti-
cles. We substituted the igVR domain of the JFH1 virus with
that of genotype 1a, which resulted in the production of vi-
ral particles. A novel HCV chimera, using the backbone of
the JFH1 virus and the igVR of genotype 1a, can be used for
simulating an in vivo animal model and for analyzing the
immune response in future reverse-genetic studies.
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